PDCD1 and metastatic melanoma: In previous studies, we identified CTLA4 methylation as a predictive biomarker for anti-PD-1 and anti-CTLA-4-directed therapy in patients with metastatic melanoma and metastatic clear cell renal cell carcinoma [21–23].